Table 6

Pharmacokinetic parameters of PR104 metabolites
PR104 Dose Patients AUC/PR-104 dose (100*h.m2.L-1)a
Level mg/m2 (n) PR104G PR104H PR-104M PR-104S1
Group A PR104 + gemcitabine 1 140 3 1.51 ± 0.63 0.12 ± 0.02 0.022±0.002 0.021±0.006
2 275 6 1.18 ± 0.30 0.16 ± 0.03 0.015±0.002 0.020±0.006
Group B PR104 + docetaxel 60 1 200 3 0.86 ± 0.29 0.20 ± 0.06 0.016±0.003 0.010±0.003
2 400 3 1.63 ± 0.73 0.12 ± 0.03 0.016±0.002 0.042±0.022
Group C PR104 + docetaxel 60 + GCSF 1 200 3 0.47 ± 0.26 0.07 ± 0.01 0.021±0.003 0.022±0.004
2 400 3 1.75 ± 0.57 0.11 ± 0.03 0.012±0.001 0.017±0.002
3 550 3 1.56 ± 0.38 0.16 ± 0.04 0.025±0.007 0.045±0.012
4 770 6 2.56 ± 0.67 0.07 ± 0.01 0.012±0.002 0.062±0.019
5 1100 6 2.76 ± 1.68 0.09 ± 0.01 0.010±0.001 0.019±0.030
Group D PR104 + docetaxel 75 + GCSF 1 770 6 1.16 ± 0.18 0.035 ± 0.005 0.009±0.001 0.022±0.006
Historical data for PR104 alone [8,16] n/a 675 7 1.02 ± 0.24 0.06 ± 0.01 0.011 ± 0.002 0.042 ± 0.015
1100 10 2.35 ± 0.85 0.09 ± 0.01 0.015± 0.002 0.041 ± 0.009

McKeage et al.

McKeage et al. BMC Cancer 2012 12:496   doi:10.1186/1471-2407-12-496

Open Data